Repligen | RGEN - Cash And Equivalent


Repligen reported $582.65M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agilent USD 1.81B 49M Mar/2026
Align Technology USD 1.06B 35.07M Mar/2026
Bio Techne USD 209.82M 36.94M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Bruker USD 133.4M 165.4M Mar/2026
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
Dentsply International USD 190M 136M Mar/2026
General Electric Aerospace USD 10.98B 1.41B Mar/2026
Henry Schein USD 138M 18M Mar/2026
Illumina USD 1.42B 368M Dec/2025
IQVIA Holdings USD 1.95B 33M Mar/2026
Mettler Toledo International USD 66.89M 2.18M Dec/2025
Myriad Genetics USD 124.4M 25.2M Mar/2026
OraSure Technologies USD 176.96M 22.31M Mar/2026
Pacific Biosciences Of California USD 56.27M 223.23M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Repligen USD 582.65M 16.63M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Standard Biotools USD 265.77M 147.56M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Waters USD 462M 125.83M Mar/2026
West Pharmaceutical Services USD 521.4M 269.9M Mar/2026